CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0002293: Alopecia of scalpHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug174 Blood plasma Wiki 1.00
drug193 CAG length <24 Wiki 1.00
drug194 CAG length >=24 Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000505 Alopecia NIH 1.00

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.

NCT04368897 SARS-CoV 2 COVID COVID-19 Androgenetic Alopecia Androgen Receptor Abnormal Androgen Deficiency Diagnostic Test: CAG length <24 Diagnostic Test: CAG length >=24
HPO:Alopecia Alopecia of scalp Frontal balding

Primary Outcomes

Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.

Measure: Hospital-free days to Day 28 [ Time Frame: 28 days]

Time: 28 days

Description: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and death

Measure: 1. Severity of Disease

Time: Day 28

HPO Nodes